Kronos Bio names Sandra Gardiner interim CFO starting Sept 15, 2023

Kronos Bio, Inc.

Appointed interim CFO, principal financial and accounting officer effective at close of business Sept 15, 2023.
Compensation: $650 per hour paid to FLG Partners under consulting agreement; no direct employment with Kronos.
Gardiner previously served as CFO of Pulse Biosciences (PLSE) from Nov 2019 to Dec 2022 and Cutera (CUTR) from July 2017 to Nov 2019.
She currently serves as acting CFO of Anebulo Pharmaceuticals (ANEB) under an agreement ending Sept 28, 2023.
Agreement with FLG is terminable by either party on 30 days' notice; includes standard indemnification provisions.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Sandra A. Gardiner

interim Chief Financial Officer

Kronos Bio, Inc.

Effective: 2023-09-15
Filed: September 18, 2023, 7:59 PM ET

On September 14, 2023, the Board of Directors of Kronos Bio, Inc. (the “Company”) appointed Sandra A. Gardiner as the Company’s interim Chief Financial Officer, as well as the Company’s principal financial officer and principal accounting officer, effective at the close of business on September 15, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sandra A. Gardiner was appointed as interim Chief Financial Officer at Kronos Bio, Inc..

Action: appointed
Role: interim Chief Financial Officer

Exact text from the filing

On September 14, 2023, the Board of Directors of Kronos Bio, Inc. (the “Company”) appointed Sandra A. Gardiner as the Company’s interim Chief Financial Officer, as well as the Company’s principal financial officer and principal accounting officer, effective at the close of business on September 15, 2023.

View on SEC.gov

Source: SEC EDGAR

accession 0001140361-23-044241

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.